New Glatiramer Acetate treatment regimen reduced relapses
Posted: Mon Jul 01, 2013 5:33 am
New Glatiramer Acetate treatment regimen reduced annualised relapse rates in MS
Teva Pharmaceutical Industries Ltd. has announced that data from the Glatiramer Acetate Low-frequency Administration (GALA) study, published in the Annals of Neurology, show that a 40mg/ 1mL dose of Copaxone(R) (glatiramer acetate injection) administered subcutaneously three times per week significantly reduced relapse rates at 12 months and demonstrated a favorable safety and tolerability profile in patients with relapsing-remitting multiple sclerosis (RRMS). Currently, the approved dose for Copaxone(R) is 20mg/ 1mL, which is a once a day subcutaneous injection....... Read More - http://www.ms-uk.org/index.cfm/copaxone
Teva Pharmaceutical Industries Ltd. has announced that data from the Glatiramer Acetate Low-frequency Administration (GALA) study, published in the Annals of Neurology, show that a 40mg/ 1mL dose of Copaxone(R) (glatiramer acetate injection) administered subcutaneously three times per week significantly reduced relapse rates at 12 months and demonstrated a favorable safety and tolerability profile in patients with relapsing-remitting multiple sclerosis (RRMS). Currently, the approved dose for Copaxone(R) is 20mg/ 1mL, which is a once a day subcutaneous injection....... Read More - http://www.ms-uk.org/index.cfm/copaxone